Search results
Understanding Blood Transfusion as a Treatment for Anemia
Verywell Health via Yahoo News· 2 days agoCertain health conditions, such as bone marrow disorders, intestinal bleeding, or cancer, may lead...
Chronic Myelogenous Leukemia (CML): 5 Things to Know
Medscape· 7 days agoAdvanced and emerging therapies in CML offer significantly improved survival. These five things to know will help elucidate potential pitfalls and pearls...
$2.7 million grant to explore hypoxia’s impact on blood stem cells
Newswise· 4 days agoA new four-year, $2.7 million grant from the National Institute of Diabetes and Digestive and Kidney...
Non-profit organization, Gift of Life, gives a flash a second chance at life
Kentwired.com· 6 days agoThe non-profit organization Gift of Life provides donations for those in need of bone marrow transplants and stem cells. This came in handy for freshman ...
Patient, 59, 'at death's door' before cancer drug ‘eradicated’ disease in months
The US Sun· 6 days agoA MAN "at death's door" after running out of treatment options for leukaemia became the second...
Europe Approves Paroxysmal Nocturnal Hemoglobinuria Drug
Medscape· 7 days agoThe factor D inhibitor danicopan has been approved for use in Europe for patients with paroxysmal...
MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation...
Digital Journal· 5 days agoAbout Myelofibrosis Myelofibrosis is a blood cancer - belonging to a group of diseases called myeloproliferative neoplasms - caused by genetic abnormalities in bone
What Is Amyloidosis?
Health via Yahoo News· 5 days ago...Chemotherapy: Helps keep misfolded plasma cells from spreading Stem cell transplant: Removes stem cells from a person without amyloidosis to inject...
Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric...
Fort Wayne Journal Gazette· 6 days agoNovartis today announced that the U.S. Food and Drug Administration (FDA) approved Lutathera®...
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives $52.13 Average PT from Analysts
ETF DAILY NEWS· 4 days agoShares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Free Report) have been given a consensus rating of “Moderate Buy” by the nine analysts that are presently covering the firm, Marketbeat ...
